Cystic Fibrosis Patient Testimony on Orkambi

Orkambi is a combination therapy for treatment of cystic fibrosis. The FDA approval for the therapy was announced on July 2nd, 2015.

This is Kate Marshall’s Orkambi testimony before the Open Public Hearing OPH portion of the May 12, 2015 Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting in Washington, DC.

Kate is 15 years old and has two copies of the D508 gene, which Orkambi, (the combination of Ivacaftor and Lumacaftor) treats.

Learn more about Orkambi here: http://bit.ly/1jCoQUT

Read all the latest news about Orkambi here: http://bit.ly/1RlPwnh

Leave a Comment

Your email address will not be published. Required fields are marked *